Navigation Links
Anti-osteoporosis Drugs Could Result in Irregular Heart Rhythm, New Study

Research has revealed some disturbing link between Reclast, made by Novartis AG and Fosamax manufactured by Merck and Co and irregular heart rhythm//, though only in a small number of women users. Both are known bone-building drugs.

The signs of a problem seem to be more pronounced with Reclast, given as an annual shot. But there was a hint of similar trouble in a few women who took the leading osteoporosis pill, Fosamax by Merck & Co. They are all at risk for a condition called atrial fibrillation, an irregular heart rhythm that can cause strokes.

Though it is still uncertain how big a worry it might be, experts agreed the overall risk is small. They said women at high risk for bone breaks _ the main target of these osteoporosis drugs _ should keep taking them as prescribed.

Two separate reports published Thursday in The New England Journal of Medicine point to elevated rates of serious episodes of that heart condition in women.

"For the first time, there may be a side effect," said a researcher involved in both studies, Dr. Steven Cummings of California Pacific Medical Center Research Institute. Until now, people have assumed Fosamax "was completely safe and could be given to almost anybody."

Fosamax, the Merck brand name for alendronate, is now used by an estimated 1.8 million American women. In a letter to the medical journal, Cummings reported evidence of the heart problem found in a recent review of a 1997 Merck-sponsored study of postmenopausal women on Fosamax.

There appeared to be 50 percent more risk of the serious heart rhythm in women who took the daily pill than among those who didn't take it. About half of the 6,459 women took Fosamax, and 47 developed atrial fibrillation, compared to just 31 cases among the other women.

However, the finding, while not statistically definitive for Fosamax, worried some researchers because it is in line with the results of a new study published in th e same issue of the medical journal.

This study of 7,736 postmenopausal women with bone-thinning osteoporosis focuses on Reclast. Novartis recently won approval to sell Reclast, known generically as zoledronic acid, for Paget's disease, another bone condition. The company hopes to get an OK later this year to sell it for osteoporosis use.

The new study, funded by Novartis, shows that Reclast works at least as well as existing drugs in the same class, researchers say. However, the risk of a serious case of irregular heart rhythm was more than double that in the other patients _ 50 cases in the drug-taking half, compared to 20 cases in the others.

Researchers cautioned about overestimating the importance of the heart rhythm problem. The Reclast study showed little apparent difference in overall cardiac deaths and the overall risk of the rhythm condition remained small.

Doctors made available by Merck and Novartis said the side effect could be a statistical fluke or just a product of aging. They said earlier studies showed no sign of the possible side effect.

For now, it's unknown if the possible risk applies to other drugs in the class known as biphosphonates. Future studies are expected to help clarify the risk.
SRM/B
'"/>




Related medicine news :

1. Vitamin D or Anti-osteoporosis Drug Reduces Bone Loss from Binge Drinking
2. Lean Protein Could Be Key to Obesity Drugs
3. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
4. Nasal Spray Could Take Drugs Direct to Brain.
5. Emphasis to ban Drugs ads by Doctors
6. Osteoporosis Drugs: right time to take-off
7. Drugs disrupt formation of blood vessels
8. Drugs to stop burgeon of HIV
9. Misleading Advertisements for Prescription Drugs
10. Drugs For Anthrax May Interfere With Oral Contraceptives
11. Over-The-Counter Drugs May Prevent Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... May 31, 2016 , ... ... technology solutions to the healthcare industry, The University of Scranton is adding a ... accelerated path to a career in rapidly growing field of healthcare information. ...
(Date:5/30/2016)... ... ... As the CDC relaxes its stance on traditional No-Nit policies, parents wonder ... lice free. , According to a May 26 article from news source ... classroom despite the fact that they may be harboring an infestation. Previous No-Nit policies ...
(Date:5/30/2016)... , ... May 30, 2016 , ... ... 6th, while Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts ... annual overnight summer camp offers families and children a fun and unique experience ...
(Date:5/29/2016)... North Carolina (PRWEB) , ... May 29, 2016 , ... ... Now, via Amazon.com, their new KlipPro KP-240L clipper is available to the public. This ... which is substantially wider than the average clipper. , Everything about this product ...
(Date:5/28/2016)... ... ... "Color Grading media can be time consuming but with FCPX LUT Night ... Austin - CEO of Pixel Film Studios. , With the FCPX LUT Night ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... , Isansys  Lifecare, a new generation ... Engine wireless patient monitoring platform, as it ships more systems ... , Scotland and Norway ... generation system, launched earlier this year, is now being used in ... , This new technology significantly enhances the user experience ...
(Date:5/31/2016)... 2016 194 Mitgliedsstaaten ... Eliminierung von viraler Hepatitis    Am ... eingegangen, virale Hepatitis bis 2030 zu eliminieren. ... Assembly haben sich die Staaten einstimmig dafür entschieden, ... Viral Hepatitis Strategy) zu verabschieden, was das bisher ...
(Date:5/31/2016)... May 31, 2016 RnRMarketResearch.com adds ... with comparative analysis of Asthma therapy at various stages, ... route of administration (RoA) and molecule type, along with ... also reviews key players involved in the therapeutic development ... projects. Complete report on H1 2016 pipeline ...
Breaking Medicine Technology: